U.S. Hospitality Stock News

Even though Xos, Inc. ( NASDAQ:XOS ) has fallen by 13% over the past week , insiders who sold US$124k worth of stock...

Key Insights Significant control over Aquestive Therapeutics by retail investors implies that the general public has...

GoPro, Inc. ( NASDAQ:GPRO ) shares have retraced a considerable 25% in the last month, reversing a fair amount of their...

With the business potentially at an important milestone, we thought we'd take a closer look at BioRestorative...

Primech Holdings Ltd. ( NASDAQ:PMEC ) shareholders won't be pleased to see that the share price has had a very rough...

Madrigal Pharmaceuticals (MDGL) remains in the red, with losses widening at a 15.3% annual rate over the last five years and net profit margins not improving in that period. Looking ahead, analysts forecast annual revenue growth of 34.8% and earnings growth of 67.2% per year, setting the company on a path to profitability within three years. This represents a much faster trajectory than the US market’s projected 10.5% revenue growth. With shares trading below an estimated fair value and the...

Thinking about whether First Solar could be a hidden gem, or if the big run-up is already behind us? You are not alone in wondering if today's price actually reflects the real value. The stock has soared lately, jumping 9.6% in the last week, 14.2% over the past month, and it is now up an impressive 40.9% year-to-date. Momentum picked up after the company landed new utility-scale solar contracts and lawmakers in Washington moved closer to passing clean energy incentives. These recent...

Ever found yourself wondering if Liquidia’s explosive growth means it’s a bargain or a bubble? Let’s break down whether there’s still value left for investors. This stock has been on a roll lately, soaring 20.6% in the past week, up 24.4% over the month, and a massive 130.7% year-to-date, topping off a 167.6% gain in the past year. Recent momentum goes beyond simple trading swings. Just last week, Liquidia announced a favorable regulatory breakthrough on its lead...

AmpliTech Group, Inc. ( NASDAQ:AMPG ) shares have retraced a considerable 28% in the last month, reversing a fair...

Wondering if KLA is a bargain or overpriced? You are not alone. With market buzz swirling, now is a great time to unpack its true value. KLA’s stock price has pulled back 1.0% over the past week, but it has still soared 8.3% in the last month and an astounding 87.5% year-to-date. This suggests big growth expectations or shifting risk perceptions. Investors have been reacting to industry trends and recent regulatory developments around semiconductor exports, shining a spotlight on companies...

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Halozyme Therapeutics (HALO) posted net profit margins of 47.9%, a significant jump from last year’s 41.4%, as earnings growth for the year hit 51.7%. This figure is twice its five-year average of 20.8% per year. Looking ahead, analysts expect earnings and revenue to continue rising by around 11.6% annually. The company’s price-to-earnings ratio of 13.4x sits comfortably below both the US biotech average of 16.9x and peers at 19.6x. Investors are eyeing the combination of strong...

In October 2025, Amphenol Corporation priced a multi-tranche debt offering totaling US$7.3 billion, issuing both fixed- and floating-rate senior unsecured notes with maturities ranging from 2027 to 2055 alongside notable third-quarter earnings results and a 52% dividend increase. This announcement reflects Amphenol’s intent to capitalize on growing demand in the IT and datacom sectors, supporting its capacity and innovation investment amid sector momentum. We’ll explore how this significant...

Insiders who acquired US$347.5k worth of Jasper Therapeutics, Inc.'s ( NASDAQ:JSPR ) stock at an average price of...

Curious if CVS Health is actually a good deal at today's price? Let's dig in and see if there's hidden value or potential caution lurking beneath the surface. CVS Health's stock has had a rollercoaster ride. It is up an impressive 76.6% year-to-date and 47.1% over the past year, though the last week was a bit rough with a 5.0% drop. Recent headlines have spotlighted CVS's strategic partnerships and accelerated moves into primary care, which are fueling discussions around its future growth...

Globe Life (GL) just released a solid batch of updates, sharing third-quarter earnings that show growth across revenue, net income, and earnings per share. The company also reported upbeat guidance and continued momentum in their share buyback plan. See our latest analysis for Globe Life. Globe Life’s latest results and upbeat guidance appear to have boosted investor confidence, with the share price returning 18.8% year-to-date and a total shareholder return of nearly 29% over the past 12...

DHT Holdings, Inc. ( NYSE:DHT ) posted some decent earnings, but shareholders didn't react strongly. We think that they...

Astronics (ATRO) has caught the attention of investors recently, with its stock experiencing some swings throughout the past month. The company’s return has climbed 2% since the start of the year and is up 36% over the past 3 months. See our latest analysis for Astronics. Momentum has clearly been building for Astronics, with the share price up an impressive 203.93% year-to-date and boasting a 158.29% total return over the past year. Recent periods have seen some give and take, but the...

Aurinia Pharmaceuticals (AUPH) has flipped to profitability after five years of transformation, posting average annual earnings growth of 43.8%. Forward guidance points to EPS growth of 17.13% per year and revenue growth of 12.5% per year, both topping the US market average of 10.5%. Improving net profit margins and high-quality earnings continue to shape investor sentiment heading into the latest results. See our full analysis for Aurinia Pharmaceuticals. Next, we will see how these...

Key Insights Neuphoria Therapeutics' estimated fair value is US$3.35 based on 2 Stage Free Cash Flow to Equity...

Curious whether Circle Internet Group is a hidden gem or overpriced in today’s market? You’re in the right place to dig into what makes this stock tick and whether the price tag matches its underlying value. Recently, the stock has been on a wild ride, climbing 33.7% year-to-date but pulling back sharply with drops of 18.3% just this past week and 23.7% over the last month. Much of this action has followed industry chatter about digital payments sector shakeups and speculation over upcoming...

The board of The Kraft Heinz Company ( NASDAQ:KHC ) has announced that it will pay a dividend on the 26th of December...

Molson Coors Beverage (TAP) is forecast to turn profitable within the next three years, with projected earnings growth of 65.59% annually. Revenue, however, is expected to rise just 0.6% per year, well below the US market average of 10.5%. While the company remains unprofitable in the latest results, losses have declined at an annual rate of 17.4% over the past five years. At $43.67 per share, TAP trades at a price-to-sales multiple of 0.8x, below both peer and sector averages, and notably...